<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ATRA is extremely effective for inducing clinical remission in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">APML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The presence of PML/RAR-alpha fusion gene produced as a result of the unique chromosomal translocation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">APML</z:e> is a marker of the sensitivity to ATRA therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Further research is needed to elucidate the mechanisms by which the development of the fusion protein in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">APML</z:e> leads to the arrest of myeloid differentiation </plain></SENT>
<SENT sid="3" pm="."><plain>ATRA leads to rapid resolution of the <z:hpo ids='HP_0003256'>coagulopathy</z:hpo> associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">APML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>There is a major clinical benefit since <z:hpo ids='HP_0003256'>coagulopathy</z:hpo> often causes early fatal <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The effectiveness of ATRA in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">APML</z:e> can serve as a paradigm for the use of differentiation therapy in human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>